Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The cell and gene therapy sectors are growing exponentially, with new players emerging daily and much progress being made both in and out of the lab. CGTLive™’s Around the Helix is your chance to catch up with the latest news in cell and gene therapies, including partnerships, pipeline updates, and more.
Have a cell and gene therapy news update you’d like to share with our editorial team? Tag us on social and use #AroundTheHelix!
The FDA has granted accelerated approval to Iovance Biotherapeutics for its tumor-derived autologous T cell immunotherapy lifileucel (branded now as Amtagvi) for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, or treated with a BRAF inhibitor with or without a MEK inhibitor in the instance that the patient is if BRAF V600 positive.
The European Commission has approved CRISPR Therapeutics and Vertex Pharma’s exagamglogene autotemcel (exa-cel; Casgevy) CRISPR-edited gene therapy for the treatment of patients who are 12 years of age and older with severe sickle cell disease (SCD) characterized by recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT), for whom hematopoietic stem cell (HSC) transplantation is appropriate and a human leukocyte antigen matched related HSC donor is not available.
The FDA has granted priority review to Sarepta Therapeutics’ efficacy supplement to its biologics license application (BLA) for delandistrogene moxeparvovec (marketed as Elevidys), a gene therapy for patients with Duchenne muscular dystrophy. The Prescription Drug User Fee Act date for the FDA’s decision on the supplement has been set for June 21, 2024.
The FDA has cleared Ascidian Therapeutics’ investigational new drug application for ACDN-01, permitting evaluation of the RNA exon editor therapy in a phase 1 trial in people with Stargardt disease.
The collaboration brings together Intellia’s proprietary CRISPR-based gene editing platform with ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle delivery platform to correct one or more cystic fibrosis (CF)-causing gene mutations.
The cells, including high-quality embryonic stem cells (SCs) and induced pluripotent stem cells, will be distributed by Charles River for research use. Pluristyx's SCs are developed with the anCELLa™ platform including its proprietary FailSafe® safety-switch technology.
Amtagvi, also known as lifileucel, was approved on February 16 for unresectable or metastatic melanoma. The FDA has approved Wuxi's Philadelphia site to begin the analytical testing and manufacturing of Amtagvi for Iovance.
TVGN-489 is a cytotoxic T lymphocyte cell therapy that recognizes multiple protein targets across the SARS-CoV-2 genome. To inform a potential trial of the therapy in long covid, Tevogen will launch a preliminary study in Q1 2024 to assess whether the development of Long COVID is associated with particular Human Leukocyte Antigens (HLA) types.
The deal between Xyphos, a subsidiary of Astellas, and Kelonia, combines Kelonia's in vivo gene placement lentiviral technology and Xyphos' ACCEL platform that uses its convertibleCAR® (convertible Chimeric Antigen Receptor) platform on immune cells.
The trials, led by cardiologist Luisa Mestroni, MD, and geneticist Matthew Taylor, MD, PhD, at University of Colorado School of Medicine, are informed by findings from a patient genetic registry dating back to 1999 in the US.
10-Year Data Show Allogeneic Stem Cell Transplant Benefits for Sickle Cell Anemia
December 10th 2024A long-term follow-up to the DREPAGREFFE-1 trial suggest that children with sickle cell anemia may benefit long-term on risk of cerebral injury, cognitive functions, and quality of life over standard care transfusions.
Autologous HCT Shows No Benefit for Patients With MCL in First Complete Remission
December 10th 2024Among those who had undetectable minimal residual disease, autologous hematopoietic cell transplantation showed signs of benefit only for those who remained MRD-positive following induction therapy.